Targeted therapy for advanced gastric cancer: A review of current status and future prospects

Table 1 Summary of completed phase III trials of targeted agents in the treatment of advanced gastric and gastroesophageal adenocarcinoma

Author/trial	Line oftreatment	Target	Agent	Treatment	ORR (%)	PFS (mo)	OS (mo)
Lordick et al[22] (2013)/ EXPAND	First	EGFR	Cetuximab	Cisplatin/capecitabine ± cetuximab	30 vs 29 P = 0.77	4.4 vs 5.6 P = 0.32	9.4 vs 10.7 P = 0.95
Waddell et al[23] (2013)/REAL-3	First	EGFR	Panitumumab	EOX ± panitumumab	46 vs 42 P = 0.42	6.0 vs 7.4 P = 0.068	8.8 vs 11.3 P = 0.013
Bang et al[32] (2010)/ ToGA	First	HER2	Trastuzumab	Cisplatin/capecitabine or 5-FU ± trastuzumab	47 vs 35 P = 0.0017	6.7 vs 5.5 P = 0.0002	13.8 vs 11.1 P = 0.0046
Hecht et al[34] (2013)/ LoGIC	First	EGFR/HER2	Lapatinib	CAPOX ± lapatinib	53 vs 40 P = NA	6.0 vs 5.4 P = 0.1	12.2 vs 10.5 P = 0.35
Ohtsu et al[37] (2011)/ AVAGAST	First	VEGF-A	Bevacizumab	Cisplatin/capecitabine ± bevacizumab	46 vs 37.4 P = 0.03	6.7 vs 5.3 P = 0.037	12.1 vs 10.1 P = 0.1002
Shen et al[39] (2015)/ AVATAR	First	VEGF-A	Bevacizumab	Cisplatin/capecitabine ± bevacizumab	40.7 vs 33.7 P = 0.348	6.3 vs 6.0 P = 0.47	11.4 vs 10.5 P = 0.55
Bang et al[35] (2014)/TyTAN	Second	EGFR/HER2	Lapatinib	Paclitaxel ± lapatinib	27 vs 9 P < 0.001	5.4 vs 4.4 P = 0.13	11.0 vs 8.9 P = 0.1044
Fuchs et al[41] (2014)/ REGARD	Second	VEGFR-2	Ramucirumab	BSC + ramucirumab or placebo	3.4 vs 2.6 P = 0.76	2.1 vs 1.3 P < 0.0001	5.2 vs 3.8 P = 0.0473
Wilke et al[43] (2014)/ RAINBOW	Second	VEGFR-2	Ramucirumab	Paclitaxel + ramucirumab or placebo	28 vs 16 P = 0.0001	4.4 vs 2.9 P < 0.0001	9.6 vs 7.4 P = 0.017
Ohtsu et al[52] (2013)/ GRANITE-1	Second or third	mTOR	Everolimus	Everolimus or placebo	4.5 vs 2.1 P = NA	1.7 vs 1.4 P < 0.001	5.4 vs 4.3 P = 0.124

ORR: Overall response rate; PFS: Progression-free survival; OS: Overall survival; EGFR: Epidermal growth factor receptor; EOX: Epirubicin, oxaliplatin and capecitabine; HER2: Human epidermal growth factor receptor 2; 5-FU: 5-fluorouracil; CAPOX: Capecitabine and oxaliplatin; NA: Not available; VEGF-A: Vascular endothelial growth factor A; VEGFR-2: Vascular endothelial growth factor receptor 2; mTOR: Mammalian target of rapamycin.